Oncolytics Biotech Inc T.ONC

Slowdown in Covid-19 sales will further move Pfizer to M&A

[Noteable]

https://www.fiercepharma.com/pharma/pfizer-set-charge-between-110-and-130-covid-vaccine-when-us-goes-commercial-model

[Noteable]

This near-term eventuality adds to the rationale for an ONCY acquisition north of US$8 Billion. 

[Buckhenry]

you folks are all over the place on wishing and hoping here. I've heard from 15 to 8 to 4 to 2.9 billion. the pattern here is no one knows squat but keep up the wishing.. its fun to read. blue skies

[Noteable]

The Global consulting companies PwC and EY have issued reports that Big Pharma has over $US1.25 Trillion in firepower and that Big Pharma's "sweet-spot" for small- medium size company M&A deals is between US$5 Billion and US$15 Billion ... so therefore a north of US$ 8 Billion deal expectation for the acquisition of ONCY is comfortably within the parameters of of Big Pharma's

[Noteable]

Last year, many on Wall Street were estimating the number of COVID-19 shots would be in line with the annual flu vaccine, now the slowing pace of the early COVID revaccination campaigns - particularly in the key U.S. market - is changing that view. A recent poll by Kaiser Family Foundation found that two-thirds of American adults do not plan on getting a COVID vaccine soon. Analysts are expecting